Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in adolescents aged 12–17 years: A systematic review and meta-analysis
The rapid emergence of COVID-19 variants of concern (VOCs) has hindered vaccine uptake. To inform policy, we investigated the effectiveness of the BNT162b2 vaccination among adolescents against symptomatic and severe COVID-19 diseases using mostly real-world data (15 studies). We searched internatio...
Main Authors: | Patrick DMC. Katoto, Jacques L. Tamuzi, Amanda S. Brand, Diana M. Marangu, Liliane N. Byamungu, Charles S. Wiysonge, Glenda Gray |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-01-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2023.2214495 |
Similar Items
-
Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (Bnt162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses
by: Patrick DMC Katoto, et al.
Published: (2023-12-01) -
Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12–17 years: A systematic review and meta-analysis
by: Patrick D. M. C. Katoto, et al.
Published: (2022-11-01) -
A racing heart post‐Pfizer/BioNTech BNT162b2
by: Hooi Khee Teo, et al.
Published: (2022-10-01) -
Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
by: Yohhei Hamada
Published: (2021-12-01) -
Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
by: Hiroaki Akiyama, et al.
Published: (2021-01-01)